Trial · NCT03151551
Participant flow22
How many started, completed or left each group, period by period.
1 to 20 of 22
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Open-Label Treatment Period | STARTED | Ixekizumab | 283 | |
| Open-Label Treatment Period | STARTED | Adalimumab | 283 | |
| Open-Label Treatment Period | Received at Least One Dose of Study Drug | Ixekizumab | 283 | |
| Open-Label Treatment Period | Received at Least One Dose of Study Drug | Adalimumab | 283 | |
| Open-Label Treatment Period | IXE 160 mg at Baseline, 80 mg Q2W/Q4W | Ixekizumab | 49 | |
| Open-Label Treatment Period | IXE 160 mg at Baseline, 80 mg Q2W/Q4W | Adalimumab | 0 | |
| Open-Label Treatment Period | IXE 160 mg at Baseline, 80 mg Q4W | Ixekizumab | 218 | |
| Open-Label Treatment Period | IXE 160 mg at Baseline, 80 mg Q4W | Adalimumab | 0 | |
| Open-Label Treatment Period | ADA 80 mg at Baseline, 40 mg Q2W | Ixekizumab | 0 | |
| Open-Label Treatment Period | ADA 80 mg at Baseline, 40 mg Q2W | Adalimumab | 51 | |
| Open-Label Treatment Period | ADA 40 mg at Baseline, 40 mg Q2W | Ixekizumab | 0 | |
| Open-Label Treatment Period | ADA 40 mg at Baseline, 40 mg Q2W | Adalimumab | 219 | |
| Open-Label Treatment Period | COMPLETED | Ixekizumab | 265 | |
| Open-Label Treatment Period | COMPLETED | Adalimumab | 259 | |
| Open-Label Treatment Period | NOT COMPLETED | Ixekizumab | 18 | |
| Open-Label Treatment Period | NOT COMPLETED | Adalimumab | 24 | |
| Post-Treatment Follow-Up Period | STARTED | Ixekizumab | 265 | |
| Post-Treatment Follow-Up Period | STARTED | Adalimumab | 258 | |
| Post-Treatment Follow-Up Period | COMPLETED | Ixekizumab | 240 | |
| Post-Treatment Follow-Up Period | COMPLETED | Adalimumab | 230 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03151551/flow